Community Clinical Oncology Program

放射治疗肿瘤组(RTOG)社区临床肿瘤学计划(CCOP)的独特之处在于，它是唯一只专注于提供与放射(RT)相关的症状改善试验的CCOP，并将最先进的RT治疗试验带给CCOP社区。RTOG CCOP进行的试验只能在特定的放射治疗组中完成，例如评估缓解疼痛的骨转移瘤的不同分割计划，使用立体定向放射外科缓解脊柱转移，以及使用海马回避和放射治疗计划，以最大限度地减少脑转移瘤全脑放射治疗后的记忆损失。为了完成我们独特的使命，我们进行了重大的战略变革，包括新的PI领导层；对促进者和当前赠款期间概念开发和患者收益的障碍进行了漫长的评估；修订了委员会结构，包括新的指导/概念审查委员会，以加强科学，增加我们的投资组合，并进一步与CCOP接触并提高收益。目标包括：1)提供癌症控制研究计划，以研究预防或管理症状的干预措施，并研究有助于更早预测结果的生物措施。这一目标集中在4个对接受RT治疗的患者重要的研究主题：粘膜炎和上皮损伤的保护剂；神经认知；缓解和生活质量；以及晚期效应和生存。2)向CCOP成员提供通过RTOG获得的全套临床和翻译方案，以及3)维护进行和评估RTOG癌症控制研究影响的基础设施和工具。CCOP利用其NCI资金，通过与RTOG开发共享资源来帮助支持这些目标，包括转译研究计划、可行性审查和临床试验、教育和招聘工作组。我们过去的工作、新的愿景和战略变化将推动症状管理科学的发展，并为最终提高接受RT治疗的癌症患者的生存质量的干预措施提供证据。

The Radiation Therapy Oncology Group (RTOG) Community Clinical Oncology Program (CCOP) is unique in that it is the only CCOP focused solely on providing radiation (RT)-related symptom amelioration trials, as well as bringing state-of-the-art RT treatment trials to the CCOP community. The RTOG CCOP conducts trials that can only be accomplished in a RT specific group, such assessment of different fractionation schedules for the palliation of painful bone metastases, the use of stereotactic radiosurgery to palliate spinal metastases, and the use of hippocampal avoidance with RT treatment planning to minimize memory loss after whole brain RT for brain metastases. To meet our unique mission we have instituted significant strategic changes including new PI leadership; a lengthy evaluation of facilitators and barriers to concept development and patient accrual over the current grant period; a revised committee structure including a new Steering/Concept Review Committee to strengthen the science, increase our portfolio, and further engage the CCOPs and improve accrual. Objectives include: 1) provision of a cancer control research program to study interventions to prevent or manage symptoms, and the study of biological measures that will assist in earlier prediction of outcomes. This aim is focused on 4 research themes important to patients treated with RT: Protectants for Mucositis & Epithelial Injury; Neurocognition; Palliation & QoL; and Late Effects & Survivorship. 2) Provision of access to the full complement of clinical and translational protocols available through the RTOG to CCOP members, and 3) maintenance of an infrastructure and tools for conduct and assessment of the impact of RTOG cancer control studies. The CCOP has leveraged its NCI funding to help support these objectives by developing shared resources with the RTOG including a Translational Research Program, a Feasibility Review and Clinical Trials, Education and Recruitment Working Groups. Our past work, new vision and strategic changes will advance symptom management science and provide evidence for interventions that will ultimately improve the quality of survival for patients with cancer treated with RT.